Information for Healthcare Providers and Local Health Departments
Regarding MDHHS Influenza Antiviral Resistance Testing

For the 2016-2017 influenza season, the Michigan Department of Health and Human Services Bureau of Laboratories (MDHHS BOL) will continue antiviral resistance testing of influenza specimens. Testing at MDHHS BOL for oseltamivir resistance is currently available for 2009 A/H1N1pdm, seasonal A/H1N1, and A/H3N2 influenza specimens. No testing is currently available at MDHHS BOL for influenza B specimens.

MDHHS antiviral resistance testing will be conducted on:
1) A subset of representative surveillance specimens from across the state
2) Clinical specimens with a high index of suspicion of antiviral resistance or in which clinical treatment would be altered based upon test results

Surveillance Specimens
• Up to 10 specimens of influenza A/H3 and A/H1N1subtypes are expected to be tested bi-weekly
• Specimens will be representatively drawn from submissions to MDHHS BOL
• Results for 2009 A/H1N1pdm specimens testing positive for a mutation conferring antiviral resistance will be communicated to submitters and local health departments
• If a specimen submitted by your facility tests positive for antiviral resistance, you may be contacted by MDHHS or local health department staff for additional epidemiologic information

Clinical Specimens
• Individual requests for MDHHS antiviral resistance testing will be reviewed by the MDHHS Division of Communicable Disease on a case-by-case basis for patients with a positive laboratory test for influenza A
• For testing approval, please call (517) 335-8165 with the following patient information:
  o Demographic information
  o Underlying medical conditions and current medications
  o Influenza vaccination history
  o Course of current illness
  o Influenza laboratory testing results (i.e., specimen collection dates, test type, lab name)
  o Antiviral therapy (i.e., start and end dates, dosage, prophylaxis or treatment)
• Cases approved for MDHHS antiviral resistance testing will be given additional specimen submission information upon approval
• Results for specimens testing positive for an antiviral resistance mutation will be communicated to submitters and local health departments; submitters will also receive negative results

Questions? Please call the MDHHS Division of Communicable Disease at (517) 335-8165

9/30/2016